相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs
Julie A. Lynch et al.
CLINICAL LUNG CANCER (2017)
Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy
Daniel J. Becker et al.
CLINICAL LUNG CANCER (2017)
Inequalities in lung cancer: a world of EGFR
Melodie Carbonnaux et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Variations in Receipt of Curative-Intent Surgery for Early-Stage Non-Small Cell Lung Cancer (NSCLC) by State
Helmneh M. Sineshaw et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Validation of Claims Algorithms for Progression to Metastatic Cancer in Patients with Breast, Non-small Cell Lung, and Colorectal Cancer
Beth L. Nordstrom et al.
FRONTIERS IN ONCOLOGY (2016)
Genomic alterations in lung adenocarcinoma
Siddhartha Devarakonda et al.
LANCET ONCOLOGY (2015)
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
Yuankai Shi et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial
Vanesa Gregorc et al.
LANCET ONCOLOGY (2014)
The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer
Wallace L. Akerley et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Neal I. Lindeman et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non-Small-Cell Lung Cancer
Thomas E. Stinchcombe et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528
Oliver Gautschi et al.
LUNG CANCER (2013)
Socioeconomic Inequalities in Lung Cancer Treatment: Systematic Review and Meta-Analysis
Lynne F. Forrest et al.
PLOS MEDICINE (2013)
VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
J. L. Kuiper et al.
BRITISH JOURNAL OF CANCER (2012)
Non-Small Cell Lung Cancer
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial
David P. Carbone et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
Vicki Leigh Keedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Phillip G. Febbo et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2011)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw et al.
LANCET ONCOLOGY (2011)
Race and Sex Differences in the Receipt of Timely and Appropriate Lung Cancer Treatment
Lisa R. Shugarman et al.
MEDICAL CARE (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Racial disparities in cancer therapy - Did the gap narrow between 1992 and 2002?
Gary R. Gross et al.
CANCER (2008)
The effect of race on invasive staging and surgery in non-small-cell lung cancer
CS Lathan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
